PET-CT Improved High-risk Prostate Cancer Staging in Trial

In a recent phase 3 trial, a novel imaging technique that identifies prostate-specific membrane antigen (PSMA) on tumor cells was more accurate than the scans typically used to stage high-risk prostate cancer before surgery or radiotherapy. The crossover study compared a combination of PSMA positron emission tomography (PET) and computed tomography (CT) —or PSMA PET-CT—with conventional imaging using CT and bone scans.
Source: JAMA - Category: General Medicine Source Type: research